| Domain | FG syndrome 4-specific finding | Broader CASK-spectrum context (clearly labeled) | Suggested ontology/identifier | Evidence caveat |
|---|---|---|---|---|
| Disease entity | FG syndrome 4 is a rare Mendelian/X-linked neurodevelopmental disorder entity linked to **CASK**; Open Targets maps **FG syndrome 4** to **MONDO:0010318** with one associated target, **CASK** (pqac-00000001) | **Broader CASK spectrum:** CASK-related disorders include MICPCH, X-linked intellectual disability, epilepsy, congenital nystagmus, hearing impairment, and other neurodevelopmental phenotypes (pqac-00000005) | **MONDO:0010318**; **CASK / ENSG00000147044** | Direct FG syndrome 4-specific literature is sparse; much modern interpretation relies on broader CASK-disorder evidence (pqac-00000001, pqac-00000005) |
| Causal gene | Historical FGS4 locus was mapped to **Xp11.4-p11.3** and is now supported as a **CASK**-associated entity (pqac-00000001) | **Broader CASK spectrum:** CASK is an X-chromosomal gene at **Xp11.4** encoding a MAGUK-family multidomain scaffold/atypical kinase (pqac-00000002, pqac-00000014, pqac-00000017) | **CASK / ENSG00000147044**; locus label **Xp11.4-p11.3** | Gene assignment is strong at disease-platform level, but FGS4 nosology historically overlapped with other FG syndromes (pqac-00000001) |
| Inheritance | **X-linked inheritance** is the best-supported inheritance model for FG syndrome 4 via CASK (pqac-00000001) | **Broader CASK spectrum:** severe phenotypes often occur in hemizygous males; heterozygous females more commonly survive with variable severity influenced by X-inactivation; many cases are de novo (pqac-00000002, pqac-00000006, pqac-00000007) | Inheritance label: **X-linked** | Sex-specific expression and severity are inferred largely from broader CASK cohorts rather than FG syndrome 4-only case series (pqac-00000002, pqac-00000007) |
| Core phenotype | FG syndrome 4 is best understood as a syndromic neurodevelopmental disorder with intellectual/developmental impairment and neurologic abnormalities due to CASK dysfunction (pqac-00000001) | **Broader CASK spectrum:** intellectual disability in 96.1% of males and 93.5% of females; microcephaly/MICPCH in 76.0% of males and 87.7% of females; epilepsy in 54.1% of males vs 36.1% of females (pqac-00000007) | HPO suggestions: **Intellectual disability**, **Global developmental delay**, **Microcephaly**, **Seizure**, **Nystagmus** | These percentages are from aggregated CASK-related disorder reviews, not FG syndrome 4-specific cohorts (pqac-00000007) |
| Neuroimaging/anatomy | FG syndrome 4 likely belongs within the CASK-linked hindbrain/pontocerebellar phenotype spectrum rather than a purely dysmorphic FG syndrome concept (pqac-00000001, pqac-00000005) | **Broader CASK spectrum:** pontocerebellar hypoplasia on MRI is common; in one 41-patient MICPCH cohort, brain MRI confirmed pontocerebellar hypoplasia in all patients studied; progressive microcephaly is characteristic (pqac-00000004, pqac-00000009) | UBERON suggestions: **cerebellum**, **pons**, **brainstem** | MRI findings are firmly established for CASK-related MICPCH, but not necessarily reported in every FG syndrome 4-labeled case (pqac-00000004, pqac-00000009) |
| Additional phenotypes | FG syndrome 4 can include ophthalmologic and movement-related manifestations under the CASK-linked phenotype umbrella (pqac-00000001, pqac-00000005) | **Broader CASK spectrum:** dystonia, scoliosis, growth retardation, optic atrophy, deafness/hearing loss, hypotonia, and congenital nystagmus are recurrent findings; in a 13-patient series, phenotype included psychomotor retardation, severe intellectual disability, progressive microcephaly, dystonia, mild dysmorphism, scoliosis, and frequent ophthalmologic anomalies/deafness/epilepsy (pqac-00000004, pqac-00000006) | HPO suggestions: **Hypotonia**, **Dystonia**, **Scoliosis**, **Sensorineural hearing impairment**, **Optic atrophy** | Feature frequencies vary by cohort composition and sex; direct FG syndrome 4 frequency estimates are unavailable (pqac-00000004, pqac-00000008) |
| Variant classes | FG syndrome 4 is associated with pathogenic **germline CASK variants**; altered gene product sequence is the current platform-level consequence annotation (pqac-00000001) | **Broader CASK spectrum:** nonsense, frameshift, missense, splice, and copy-number variants are all reported; one MICPCH cohort identified 23 point mutations and 9 copy-number variants among 41 patients; all tested parental samples but one were de novo (pqac-00000004, pqac-00000005, pqac-00000007) | Variant class labels: **missense**, **frameshift**, **nonsense**, **splice-site**, **copy-number variant** | No single recurrent FG syndrome 4 founder variant is established from current retrieved evidence (pqac-00000004, pqac-00000007) |
| Molecular mechanism | FG syndrome 4 is mechanistically attributable to loss or disruption of **CASK** function in neuronal development and synaptic systems (pqac-00000001) | **Broader CASK spectrum:** CASK is a multidomain scaffold/atypical kinase with CaMK, L27, PDZ, SH3, and GuK domains; it binds neurexin, liprin-α, SAP97, Tbr1, CINAP and others; disease-associated missense variants can impair neurexin binding/oligomerization and alter transcriptional or receptor-trafficking functions (pqac-00000010, pqac-00000013, pqac-00000015, pqac-00000016, pqac-00000017) | GO suggestions: **synapse organization**, **protein localization to synapse**, **regulation of transcription**, **receptor trafficking** | Mechanistic conclusions derive mainly from broader CASK molecular studies rather than FGS4-labeled patient studies (pqac-00000010, pqac-00000015, pqac-00000017) |
| Pathophysiology chain | Upstream event: pathogenic CASK variant; intermediate effects: altered scaffolding/protein interactions and neuronal growth regulation; downstream manifestations: developmental delay, microcephaly, pontocerebellar hypoplasia, seizures, visual/oculomotor abnormalities (pqac-00000001, pqac-00000005) | **Broader CASK spectrum:** evidence supports non-cell-autonomous postnatal brain growth defects, cerebellar granule-cell vulnerability, altered excitatory/inhibitory balance, and possible metabolic/mitochondrial stress contributions (pqac-00000003, pqac-00000010, pqac-00000011, pqac-00000013) | GO suggestions: **postnatal brain development**, **neuron death**, **synaptic signaling**; CL suggestions: **cerebellar granule cell**, **Purkinje cell**, **retinal ganglion cell** | Causal chain remains incompletely resolved; synaptic dysfunction alone may be insufficient to explain degeneration (pqac-00000010, pqac-00000013) |
| Diagnosis | Suspect FG syndrome 4 in individuals with X-linked/syndromic neurodevelopmental disorder features and confirm by **molecular testing of CASK** (pqac-00000001) | **Broader CASK spectrum:** diagnosis commonly uses exome/genome sequencing or copy-number analysis; CASK screening is especially relevant in microcephaly with pontocerebellar hypoplasia; MRI is supportive; parental testing helps establish de novo status and counseling (pqac-00000002, pqac-00000004) | Testing identifiers: **CASK sequencing**, **copy-number analysis**, **brain MRI** | No disease-specific consensus diagnostic criteria for FG syndrome 4 were identified in retrieved evidence (pqac-00000002, pqac-00000004) |
| Differential diagnosis | FG syndrome 4 should be distinguished from other historically named FG syndromes and from other pontocerebellar hypoplasia disorders (pqac-00000001) | **Broader CASK spectrum:** differential diagnosis includes other genetic causes of MICPCH/PCH and neurodevelopmental disorders with microcephaly, seizures, or nystagmus; genetic heterogeneity in MICPCH includes non-CASK genes such as ITPR1, RELN, DYNC1H1, DCTN1, HDAC2, MARCKS, HS3ST5 (pqac-00000002) | Disease labels: **FG syndrome 1 (MED12-related)** vs **FG syndrome 4 (CASK-related)**; broader label **pontocerebellar hypoplasia** | Historical nomenclature can mislead; older FG labels do not always map cleanly to current molecular nosology (pqac-00000001, pqac-00000002) |
| Treatment/management | No FG syndrome 4-specific disease-modifying therapy was identified in retrieved evidence | **Broader CASK spectrum:** management is supportive/symptomatic and multidisciplinary, including developmental therapies, seizure management, hearing/vision support, orthopedic monitoring (e.g., scoliosis), nutrition, and genetic counseling; PCH reviews state treatment is still symptomatic (pqac-00000004, pqac-00000008) | NCIT suggestions by label: **Physical Therapy**, **Occupational Therapy**, **Speech Therapy**, **Anticonvulsant Therapy**, **Genetic Counseling** | Management recommendations are inferred from CASK/PCH practice patterns; no controlled FG syndrome 4 treatment trials were found (pqac-00000004, pqac-00000008) |
| Prognosis | FG syndrome 4 prognosis is undefined due to rarity and sparse direct follow-up data | **Broader CASK spectrum:** severity is highly variable; hemizygous males with null variants may be very severe or lethal, whereas heterozygous females can survive with lifelong disability; one cohort showed only 6/41 could walk and 3/41 could speak, underscoring substantial morbidity (pqac-00000004, pqac-00000006) | Outcome labels: **lifelong neurodevelopmental disability**, **variable severity** | No robust disease-specific survival curves, life expectancy estimates, or mortality rates were identified (pqac-00000004, pqac-00000006) |
| Epidemiology | No reliable prevalence or incidence estimate for **FG syndrome 4** was identified in retrieved evidence | **Broader CASK spectrum:** disease is rare and likely under-ascertained; published cohorts are small and enriched for severe neurodevelopmental referral populations (pqac-00000002, pqac-00000008) | MONDO entity: **MONDO:0010318** | Absence of epidemiologic estimates should be treated as a knowledge gap, not evidence of extreme rarity thresholding (pqac-00000002, pqac-00000008) |
| Environment/prevention | No established environmental risk, protective factor, infectious trigger, or gene-environment interaction was identified for FG syndrome 4 | **Broader CASK spectrum:** prevention is primarily genetic/reproductive—family testing when indicated, recurrence-risk counseling, and consideration of prenatal or preimplantation testing after familial variant identification (supported by de novo but occasionally inherited/mosaic contexts) (pqac-00000004) | Prevention labels: **genetic counseling**, **prenatal testing** (label only) | This is a Mendelian disorder; non-genetic prevention evidence was not found in retrieved sources (pqac-00000004) |
| Clinical trials / real-world implementation | No FG syndrome 4- or CASK-specific interventional therapeutic trial was retrieved | **Broader CASK spectrum:** a broad observational genotype-first registry, **Simons Searchlight** (**NCT01238250**), is recruiting and may capture natural-history/phenotype data across rare neurodevelopmental genetic disorders | **NCT01238250** | Observational registry participation is not evidence of efficacy for any therapy (pqac-00000001) |
| Model organisms | No FG syndrome 4-specific animal model named as such was identified | **Broader CASK spectrum:** Cask-null mice die within hours of birth; Cask heterozygous females recapitulate microcephaly, cerebellar hypoplasia, optic nerve hypoplasia, scoliosis, and occasional seizures; post-developmental deletion causes cerebellar degeneration and ataxia; Drosophila and C. elegans models show conserved but partial phenotypes (pqac-00000011, pqac-00000012, pqac-00000013) | Model labels: **mouse**, **Drosophila**, **C. elegans** | Models capture major neurodevelopmental aspects but incompletely reproduce human phenotypic breadth and sex-specific mosaic biology (pqac-00000011, pqac-00000012, pqac-00000013) |
| Recent developments (2023-2024) | For FG syndrome 4 specifically, recent advances mainly come through the broader CASK literature rather than disease-specific series | **Broader CASK spectrum:** 2023 review quantified sex-stratified phenotype frequencies and domain–phenotype relationships; 2024 work highlighted splicing-dependent structural plasticity and vertebrate-specific exon effects; 2024 reviews summarized broader CASK mechanisms (pqac-00000005, pqac-00000007) | Recent-source markers: **2023 review**, **2024 mechanistic study** | These are important for interpretation, but not direct therapeutic breakthroughs for FG syndrome 4 (pqac-00000005, pqac-00000007) |


*Table: This table condenses high-yield knowledge-base facts for FG syndrome 4, clearly separating direct FG syndrome 4 evidence from broader CASK-related disorder evidence. It is useful for curation because the disease-specific literature is sparse and much current understanding is inferred from the larger CASK clinical and mechanistic spectrum.*